188 related articles for article (PubMed ID: 26070546)
1. Determinants of successful ablation and complete remission after total thyroidectomy and ¹³¹I therapy of paediatric differentiated thyroid cancer.
Verburg FA; Mäder U; Luster M; Hänscheid H; Reiners C
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1390-8. PubMed ID: 26070546
[TBL] [Abstract][Full Text] [Related]
2. Recurrent disease in juvenile differentiated thyroid carcinoma: prognostic factors, treatments, and outcomes.
Mihailovic J; Nikoletic K; Srbovan D
J Nucl Med; 2014 May; 55(5):710-7. PubMed ID: 24722527
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
4. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
5. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
6. The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma.
Thies ED; Tanase K; Maeder U; Luster M; Buck AK; Hänscheid H; Reiners C; Verburg FA
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2281-90. PubMed ID: 25030619
[TBL] [Abstract][Full Text] [Related]
7. Thyroid lobe ablation with iodine- ¹³¹I in patients with differentiated thyroid carcinoma: a randomized comparison between 1.1 and 3.7 GBq activities.
Giovanella L; Piccardo A; Paone G; Foppiani L; Treglia G; Ceriani L
Nucl Med Commun; 2013 Aug; 34(8):767-70. PubMed ID: 23652210
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of differentiated thyroid carcinoma in children and adolescents.
Negre Busó M; García Burillo A; Simó Perdigó M; Galofré Mora P; Boronat de Ferrater M; Cuberas Borrós G; Sábado Álvarez C; Castell Conesa J
J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1431-1441. PubMed ID: 32877364
[TBL] [Abstract][Full Text] [Related]
9. [Relapse of differentiated thyroid carcinoma in low-risk patients].
Krajewska J; Czarniecka A; Jarzab M; Kukulska A; Hankiewicz-Junak D; Hasse-Lazar K; Gubała E; Puch Z; Paliczka E; Roskosz J
Endokrynol Pol; 2006; 57(4):386-91. PubMed ID: 17006841
[TBL] [Abstract][Full Text] [Related]
10. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer.
Handkiewicz-Junak D; Wloch J; Roskosz J; Krajewska J; Kropinska A; Pomorski L; Kukulska A; Prokurat A; Wygoda Z; Jarzab B
J Nucl Med; 2007 Jun; 48(6):879-88. PubMed ID: 17536106
[TBL] [Abstract][Full Text] [Related]
11. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer.
Lim I; Kim SK; Hwang SS; Kim SW; Chung KW; Kang HS; Lee ES
Ann Nucl Med; 2012 Dec; 26(10):777-86. PubMed ID: 22869417
[TBL] [Abstract][Full Text] [Related]
13. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
14. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
[TBL] [Abstract][Full Text] [Related]
15. Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level.
Hänscheid H; Verburg FA; Biko J; Diessl S; Demidchik YE; Drozd V; Reiners C
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1296-302. PubMed ID: 21461735
[TBL] [Abstract][Full Text] [Related]
16. Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan.
Hommel I; Pieters GF; Rijnders AJ; van Borren MM; de Boer H
Neth J Med; 2016 May; 74(4):152-7. PubMed ID: 27185773
[TBL] [Abstract][Full Text] [Related]
17. Parameters Influencing Curative Effect of 131I Therapy on Pediatric Differentiated Thyroid Carcinoma: A Retrospective Study.
Xu L; Liu Q; Liu Y; Pang H
Med Sci Monit; 2016 Aug; 22():3079-85. PubMed ID: 27576533
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients.
Verburg FA; de Keizer B; Lips CJ; Zelissen PM; de Klerk JM
Eur J Endocrinol; 2005 Jan; 152(1):33-7. PubMed ID: 15762184
[TBL] [Abstract][Full Text] [Related]
19. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
[TBL] [Abstract][Full Text] [Related]
20. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.
Kim TY; Kim WB; Kim ES; Ryu JS; Yeo JS; Kim SC; Hong SJ; Shong YK
J Clin Endocrinol Metab; 2005 Mar; 90(3):1440-5. PubMed ID: 15613412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
